A Phase 1, Multicenter, Open-label, Multiple Dose escalation Study of ARX788, Intravenously Administered as a Single Agent in Subjects with Advanced Cancers with HER2 Expression

Markman, Ben (Primary Chief Investigator (PCI))
Frentzas, Sophia (Primary Chief Investigator (PCI))

Project: Research

Project Description

NMA HREC Reference Number: HREC/17/MonH/354
Monash Health Ref: RES-17-0000-531A

Status	Active
Effective start/end date	16/11/18 → 15/11/24

Keywords

clinical trial
treatment efficacy
advanced cancer